Daily Brief Archive: July 8, 2026 — U.S. & Hong Kong Stock Analysis

Free preview

U.S. Markets

  • Chips sold again: Samsung's print missed the loftiest bar and DeepSeek's own-chip report hit — Nasdaq -1.2%
  • S&P -0.45% to 7,503.85, SMH down 3%+ as pricey AI names see profit-taking
  • Iran hit a tanker near Hormuz: Brent +3% to $74.16, energy led with XLE +2.8%
  • Rivian's 75M-share, $1.5B offering triggered an 18% dilution rout
  • Vertex's $10B all-cash Crinetics buyout ($85/share) stokes the biotech M&A wave

Hong Kong

  • HK opened soft and closed broadly higher, HS Tech leading; Tencent up seven straight
  • Beaten-down internet repairs: Alibaba, Xiaomi and Kuaishou all up 2%+ early
  • Domestic-compute narrative builds: Meituan's LongCat-2.0 trained fully on local silicon; Biren +10%
  • UBTECH fell another 5.8% as the robotics cool-down continues
  • The tanker attack lifted energy; the big-three Chinese oils bounced from oversold

Today's Watchlist

  • SK Hynix lists on Nasdaq Jul 10 — memory-trade money faces reallocation
  • Tesla earnings Jul 22 and AMD's Advancing AI Jul 23 — two judgment days
  • If DeepSeek's own chip is confirmed, the AI-compute narrative gets rewritten
  • Hormuz heats up: the fragile US-Iran truce amplifies oil volatility
  • SpaceX -6.8% the day after inclusion — the 'inclusion marks the top' pattern strikes again

Deep Dives (3 names)

Neutral
Score6/10RSI(14) 50.4Offering size 75M shares / $1.5BOne-day drop -18.1%Position closed Stopped out -11.5%

Technicals — Down 18.1% to $16.49 — the worst day since 2024 — giving back nearly all of last week's 27% run. Barely holding the 20-day ($16.34) on 2.5x volume; real supply. Until the offering prices, upside is capped, with the 50-day ($15.6) the next support.

Fundamentals — The 75M-share, ~$1.5B raise funds equity contributions under its DoE loan (the Georgia plant) — strategically sound, near-term pure dilution. The pre-released Q2 revenue of $1.55–1.65B and raised guidance got drowned out. The fundamental direction is intact, but ~6% more shares directly dilutes per-share value.

News — The public offering announced intraday on 7/7 drove the crash — worst day since 2024, fifth-worst ever. It came one day after an 8.1% delivery-driven pop: shrewd timing (raising at highs), brutal for retail. Bloomberg and CNBC both point to the DoE loan equity-contribution use.

Short-term · 1–3 weeks
Neutral Sidelines

Position stopped out (-11.5%): the offering shattered the momentum thesis, and bids won't return until it prices. This is a discipline exit — the delivery story survives, but let the dilution digest first. Reassess on a post-pricing volume dry-up.

Entry Revisit after the offering prices and volume dries up; watch the 50-day near $15.6Stop $14.8Target $19
Long-term · months+
Neutral

The R2 ramp plus DoE-backed capacity expansion is a real growth path, but recurring capital needs make dilution the rule, not the exception. Wait for the offering to digest and Q2 to confirm the margin trajectory before a long-term case.

  • Offering overhang plus further capital needs ahead
  • EV demand swings make delivery momentum fragile
  • Tesla price cuts and competition squeeze margins
Community Voices
  • StockTwits · Yesterday's cheerleaders are today's mourners — the company hands you a share offering at peak euphoria; that's the market's sense of humorOriginal ↗
Institutional Views
  • 华尔街共识 · 27 analysts, average target $18.6 (+13% vs. spot), rating 1.74 — targets face a post-dilution reset
  • CNBC · Proceeds fund equity contributions under the DoE loan agreement, feeding the Georgia plant buildoutSource ↗
Neutral
Score6/10Deal price $85.00Acquirer VertexDeal size ~$10B all cashArb spread +1.8%

Technicals — Up 98.7% to $83.53 on 39x volume, pinned 1.8% below the $85 deal price — no longer a chart-driven stock, it's an arb instrument. Into the Q3 close it grinds toward $85, absent a topping bid or a deal break.

Fundamentals — Vertex pays $85/share in cash, ~$10B total, unanimously approved by both boards, closing in Q3. The strategic core: Palsonify for acromegaly and pipeline asset atumelnant (potential $5B+ peak sales), extending Vertex into rare endocrine disorders.

News — The deal hit pre-market 7/7 and the stock repriced in one step. It's the largest print of this biotech M&A wave — IBB just made 52-week highs (RSI 81) as big pharma sweeps late-clinical assets for cash, and the sector's 'who's next' guessing game is on.

Short-term · Into the Q3 close
Neutral Sidelines

The deal price caps the upside; the residual spread compensates deal-break risk — professional arb territory. Holders can ride to close or cash out now; fresh money has no reason to enter.

Entry Nothing here for retail: the 1.8% spread is arb-fund business, not a tradeStop —Target $85
Long-term · months+
Neutral

The company gets absorbed into Vertex in Q3 — the standalone story ends here. The real takeaway is sector-level: cash-rich pharma is sweeping, and late-clinical, pre-commercial mid-caps fit this M&A wave's prey profile.

  • A deal break gives back most of the gain (unlikely but real)
  • Regulatory review drags the close
Community Voices
  • StockTwits · Yesterday's holders are popping champagne; today's buyers are annualizing 1.8% — same ticker, two different livesOriginal ↗
Institutional Views
  • 交易条款 · $85/share all cash, ~$10B, unanimously board-approved, expected to close in Q3 2026Source ↗
  • Seeking Alpha · Atumelnant's $5B+ peak-sales potential is the core chip behind Vertex's moveSource ↗
Neutral
Score6/10Above post-IPO low +1.6%Day after inclusion -6.8%IPO price $135Signal record Closed 7/7 at +1.8%, dodged today

Technicals — Down 6.8% to $149.47 the day after inclusion, within 1.6% of the $147.11 post-IPO low — the 'inclusion marks the top' pattern executed by the book. A $147 break enters price-discovery no-man's-land; a hold could build a double bottom. MAs still haven't formed; events and psychology rule.

Fundamentals — The $4.3B passive bid landed and marked the top as trapped and profit-taking supply distributed together. Fundamentals unchanged: 10.3M Starlink subs with sliding ARPU, $5B annual losses, and a $2.1T cap pricing a flawless decade. Starship flight 13 late this month is the next real catalyst.

News — Yesterday's shift to sidelines (+1.8% banked) preceded today's -6.8% — the 'inclusion top, one-month give-back' pattern struck again. Multiple desks had flagged it; mechanical passive buying is never price's friend.

Short-term · 1–3 weeks
Neutral Sidelines

Stay sidelined: the give-back isn't done, and $147 is the level everyone watches — a hold starts a double bottom, a break fires the next leg down. No need to pick a side before the Starship flight late this month.

Entry Small probe if $147 holds on drying volume; on a break, wait out price discoveryStop $143Target $170
Long-term · months+
Neutral

The launch monopoly and Starlink cash-flow layer are a real moat; $2.1T on $5B losses is a real problem. Until the give-back ends and ARPU stabilizes, wait for a fatter pitch.

  • A $147 break triggers reverse passive rebalancing
  • A Starship flight failure
  • ARPU erosion plus Amazon's LEO competition
Signal BacktestCumulative +1.83%price itself -5.12%1/1 closed trades wonprofitable since 07-04
  • 07-02Long$157.54 → closed $160.4207-07+1.83%
Community Voices
  • WSB · Mentions doubled 79→140 and the dip-buyers are queuing at $147 — the support everyone can see is usually the first to breakOriginal ↗
Institutional Views
  • 华尔街共识 · 31 analysts, average target $246.9 (+65% vs. spot) with positive ratings — coverage got more bullish into the drop
  • The Motley Fool · The inclusion premium historically unwinds over about a month — we're in the give-back leg nowSource ↗

Rapid Scan (35 names)

TickerCloseChangeScoreDirectionOne-line take
RIVN logoRIVNUS$16.49-18.12%6NeutralThe 75M-share raise crushed it -18%; momentum story broken — stopped out at -11.5%
CRNX logoCRNXUS$83.53+98.74%6NeutralVertex's $85 all-cash buyout doubled it; the remaining 1.8% spread is arb-fund food
SNDK logoSNDKUS$1,617.7-7.26%6Neutral-7.3% through the 50-day, -23% on the week; memory's weakest link, stay sidelined
SPCX logoSPCXUS$149.47-6.83%6Neutral-6.8% the day after inclusion proves the pattern; yesterday's exit dodged it — $147 is the line
B logoBUS$36.86-3.28%5NeutralGold's pullback broke the setup, -3.3%; thesis void — closed at a small -3.5% loss
ESS logoESSUS$298.32+0.11%5NeutralApartment REIT at 52-week highs, RSI 69 warm; 3.5% yield — wait for the dip
PTGX logoPTGXUS$140.85+7.11%5Neutral+7.1% to new highs but RSI 83.9 redline; chase the M&A theme only with a stop
NU logoNUUS$13.61-3.20%5Neutral-3.2% pullback after a +12% month; the LatAm neobank tests 20-day support
CVNA logoCVNAUS$67.49-4.11%5Neutral-4.1% stuck in MA chop, giving back a +7% week; no direction yet, sidelines
GNRC logoGNRCUS$235.8-8.54%4Neutral-8.5%, -18% on the week; the backup-power fever cools below the 20/50-day — sidelines
FIS logoFISUS$42.6+3.22%5Neutral+3.2% oversold bounce, +11% week; 8.2x with a 4% yield in a -48%-a-year crater
MP logoMPUS$50.49-4.75%5Neutral-4.8%, rare earths -21% on the month; the geopolitical theme ebbs, RSI 34.9 — wait
CNQ logoCNQUS$40.69+3.41%6Neutral+3.4% on the crude pop; Hormuz risk premium plus a 4.3% yield — await trend confirmation
SOLS logoSOLSUS$62.1-8.74%3Neutral-22% in two days on 4.7x volume with no bid — do not catch this knife
ESI logoESIUS$38.57-8.86%4Neutral-8.9% as the specialty-chem selling runs on volume, -17% week; let the dust settle
ORCL logoORCLUS$141.6-1.50%6Neutral-1.5%, 5% off the 52-week low at RSI 29 — third test of the $134.57 line
SNX logoSNXUS$235.67-1.36%5NeutralIT distribution -12% week at RSI 31.7; 17x after a +69% year, a deep giveback
LYB logoLYBUS$54.6+3.08%4Neutral+3.1% oversold pop; the 7.8%-yield chemicals casualty — a bounce isn't a turn
ALB logoALBUS$129.02-3.57%5Neutral-3.6% at RSI 29.3; left side of the lithium trough as the complex falls — wait for the turn
AA logoAAUS$49.01-1.72%5Neutral-1.7% at RSI 30.8, -36% month; the aluminum-beta knife is still falling
HAS logoHASUS$76.73-1.60%5Neutral-1.6% at RSI 26.7; the 3.6%-yield toy leader, oversold with no bid yet
RWT logoRWTUS$4.72+3.74%4Neutral+3.7% mortgage REIT on 9.6x volume; a 15.8% yield with matching danger
OXY logoOXYUS$51.68+5.88%6Neutral+5.9%, a top tanker-attack beneficiary; Buffett's floor plus geopolitical premium — no trend yet
NBIS logoNBISUS$195.19-8.37%5Neutral-8.4%, neocloud -24% on the week; even +444% revenue can't stop a de-rate — wait
RKLB logoRKLBUS$83.41-10.40%4Neutral-10.4%, space -27% on the month; SpaceX's slide drags the group — the $76 200-day is the floor
WULF logoWULFUS$20.24-8.87%4Neutral-8.9%, -18% week in the AI-datacenter ebb; high-beta miners fall first — wait for a sector signal
NVTS logoNVTSUS$13.99-8.14%3Neutral-8.1%, -52% on the month; the GaN theme unwinds with no bid — don't touch
PENG logoPENGUS$62.71-7.38%4Neutral-7.4% with the AI-infra pullback; profit-taking after a +189% quarter
FCEL logoFCELUS$25.96-12.68%3Neutral-12.7% as the fuel-cell frenzy ebbs; a +285%-quarter meme's volatility — don't chase
BCRX logoBCRXUS$10.99+8.06%5Neutral+8.1% to 52-week highs; small pharma riding the M&A wave, RSI 72 warm
CMPS logoCMPSUS$12.99+1.17%4Neutral+1.2% psychedelics theme chopping at highs after +129% in a quarter — pure story stock
WEN logoWENUS$7.78-1.52%4Neutral-1.5% with cooling mentions; the 7.1%-yield cigar butt as retail heat fades
POET logoPOETUS$8.27-7.60%3Neutral-7.6%, photonics -43% on the month; the high-beta tail of a fading theme
ABUS logoABUSUS$5.18+4.23%4Neutral+4.2%, the HBV-pipeline small cap at 52-week highs — an M&A-wave fringe name
SSECZUS$8.06-25.92%2Neutral-25.9% tokenization collapse; a broken IPO with no floor in sight — stay away
Stock Brief 2026-07-08: Daily U.S. & HK Market Analysis Archive · Quant Brief